RRML - An experimental in-vitro study to evaluate the anti-helicobacter activity of Glycyrrhetinic acid
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English


Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12


Advanced search


Top 10 downloaded articles
- October 2025 -
 
Romanian Review of Laboratory ... 23
The diagnostic value of lipopr... 15
Comparison of platelet suspens... 15
Investigation of cytokine chan... 12
Polymorphisms in FVL, prothrom... 12
Evaluation of the impact of vi... 11
Unlocking the future of breast... 11
ATM rs189037 polymorphism: A p... 10
Serum fibronectin and C-reacti... 9
Plasma phosphorylated neurofil... 8

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 27(1)/2019 DOI:10.2478/rrlm-2019-0003
XML
TXT

Research article

An experimental in-vitro study to evaluate the anti-helicobacter activity of Glycyrrhetinic acid

Muhammet Murat Celik, Nizami Duran

Correspondence should be addressed to: Nizami Duran

Abstract:

Aim: The aim of this study was to investigate the in-vitro efficacy of Glycyrrhetinic acid against Helicobacter pylori (H. pylori) strains, as compared with conventional antibacterial agents. Methods: A total of 41 H. pylori isolates were used, 6 of which were of standard strains (NCTC 1637), 8 of which were drug-sensitive, and 27 were resistant to drugs isolates. Clarithromycin and metronidazole resistance in all strains of H. pylori were determined by the Epsilometer test (E-test) method. MIC study was performed by using microdilution broth method. Results: Glycyrrhetinic acid was found to be effective against H. pylori NCTC 1637 in doses of 12.0±4.38 µg/mL, while the MIC value of clinical H. pylori isolates susceptible to antimicrobials was 20.8±10.11 µg/ml. It was found that the MIC values for antimicrobial-sensitive clinical H. pylori isolates was higher when compared with H. pylori NCTC 1637 strains. The MIC values of the standard antimicrobial agents against drug-resistant H. pylori strains were higher than H. pylori NCTC 1637 strains and drug-sensitive H. pylori strains. The MIC value was found to be 14.22±7.77 µg/ml for metronidazole, 3.89±1.90 µg/ml for clarithromycin, 2.33±1.0 µg/ml for amoxicillin, 2.44±0.88 µg/ml for levofloxacin and 4.89±2.47 µg/ml for tetracycline, whereas the MIC value of Glycyrrhetinic acid was 26.67±8.0 µg/ml in metronidazole-resistant H. pylori isolates. Besides, MIC values of the antimicrobials and 18ß-Glycyrrhetinic acid among the strains resistant to clarithromycin were as follows: 3.25±2.12 µg/ml for metronidazole, 9.71±4.54 µg/ml for clarithromycin, 2.06±1.32 µg/ml for amoxicillin, 3.88±4.22 µg/ml for levofloaxacin and 3.25±1.04 µg/mL for tetracycline and 22.0±11.11 µg/ml for Glycyrrhetinic acid. Conclusion: Glycyrrhetinic acid had significant antimicrobial activity against H. pylori strains. Although further in-vivo studies are needed on antimicrobial activity of Glycyrrhetinic acid, increased resistance to drugs currently used in treatment suggests that Glycyrrhetinic acid may be a potential agent for the treatment of H. pylori.

Keywords: Glycyrrhetinic acid, Helicobacter pylori, drug, resistance, metronidazole, clarithromycin

Received: 17.6.2018
Accepted: 3.11.2018
Published: 6.1.2019

 
  PDF Download full text PDF
(461 KB)
     
 
How to cite
Celik MM, Duran N. An experimental in-vitro study to evaluate the anti-helicobacter activity of Glycyrrhetinic acid. Rev Romana Med Lab. 2019;27(1):63-71. DOI:10.2478/rrlm-2019-0003